← All themes

GLP-1 & Obesity

GLP-1 medicines treat obesity and diabetes, and have grown into one of the largest drug categories ever launched. Their reach extends past medicine, because a change in how much people eat moves whole consumer industries.

92 stocks

Obesity Second-Order Effects

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Pfizer PFE $168B	2,806	+71	+3%	$160B
2	2 Amgen AMGN $235B	2,134	-63	-3%	$90.3B
3	3 Eli Lilly LLY $1.12T	2,052	+30	+1%	$183B
4	4 Becton Dickinson BDX $52.8B	1,475	-12	-0.8%	$59.7B
5	5 Regeneron Pharmaceuticals REGN $82B	1,019	+47	+5%	$54.5B
6	6 McKesson MCK $116B	968	-3	-0.3%	$26.4B
7	7 AstraZeneca AZN $259B	909	+137	+18%	$31.1B
8	8 Novo Nordisk NVO $173B	805	+69	+9%	$12.7B
9	9 Conagra Brands CAG $6.77B	720	-35	-5%	$13.9B
10	10 ResMed RMD $34.1B	687	+25	+4%	$25.4B
11	11 West Pharmaceutical WST $27B	670	+30	+5%	$28.5B
12	12 Lamb Weston LW $7.47B	559	-49	-8%	$7.54B
13	13 DELISTED CATALENT, INC. CTLT	529	+20	+4%	$22.3B
14	14 DaVita DVA $12.1B	511	-4	-0.8%	$10.4B
15	15 Teva Pharmaceutical Industries Limited TEVA $47.9B	429	-11	-3%	$5.14B
16	16 Medifast MED $135M	296	-5	-2%	$1.93B
17	17 Inspire Medical Systems INSP $2.03B	253	+5	+2%	$5.91B
18	18 Accendra Health ACH $20.1M	247	-13	-5%	$2.24B
19	ARNA 19 DELISTED Arena Pharmaceuticals Inc ARNA	235	-2	-0.8%	$3.35B
20	20 Herbalife HLF $1.53B	231	-17	-7%	$4.34B
21	21 Opko Health OPK $1.2B	206	-27	-12%	$669M
22	22 DELISTED WW International WW	205	-23	-10%	$1.2B
23	TWNK 23 DELISTED Hostess Brands, Inc. Class A Common Stock TWNK	185	-5	-3%	$2.64B
24	24 MannKind Corp MNKD $1.03B	181	+12	+7%	$464M
25	25 Alaunos Therapeutics TCRT $5.54M	162	+7	+5%	$194M